WuXi AppTec entered into drug discovery collaboration with Canadian biotech

| By | AI, Drug Development, R&D
0
190

WuXi AppTec Research Service Division (China) and Cyclica (Canada) announced a multi-phase collaboration to advance drug discovery programs by driving insights into small molecule polypharmacology, while further evolving Cyclica’s biophysics and AI-augmented platform.

Through a multi-phase collaboration, WuXi will leverage and evaluate Cyclica’s cloud-based proteome Ligand Express™ screening platform to investigate the off-target profiles of small molecules, apply Cyclica’s novel and proprietary advanced AI technology to create state of the art predictive models for ADMET properties, and support the testing and optimization of Cyclica’s next generation AI-based de novo drug design technology.

WuXi AppTec is a China-based leading global contract research outsourcing provider, serving the worldwide pharmaceutical, biotech, and medical device industries.

Cyclica is a Canadian biotechnology company that is driving drug discovery by empowering scientists in pharma with an integrated cloud-based and AI-augmented platform that enhances how they design, screen and personalize medicines.

SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.